Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer Patients
Prostate cancer is a malignancy in urology with the highest incidence metastasize to the bone up to 70%. The incidence of skeletal related event (SRE) by 46.1% such as severe pain, pathologic fractures, spinal compression syndrome and hypercalcemia, with a consequence of higher inpatient care and w...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2013-01-01
|
| Series: | Acta Medica Indonesiana |
| Online Access: | http://actamedindones.org/index.php/ijim/article/view/126 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849391858041487360 |
|---|---|
| author | Ferry Safriadi |
| author_facet | Ferry Safriadi |
| author_sort | Ferry Safriadi |
| collection | DOAJ |
| description |
Prostate cancer is a malignancy in urology with the highest incidence metastasize to the bone up to 70%. The incidence of skeletal related event (SRE) by 46.1% such as severe pain, pathologic fractures, spinal compression syndrome and hypercalcemia, with a consequence of higher inpatient care and worsen the patient’s prognosis.
Androgen deprivation therapy (ADT) as a metastatic prostate cancer treatment itself causes an osteopenia or osteoporosis.
Bisphosphonate inhibits normal and pathologic osteoclast-mediated bone resorption by several mechanisms. Denosumab is the latest treatment option in bone metastases. Multi-study shows the efficacy of denosumab is better than zoledronic acid for SRE prevention. Adverse events between denosumab and bisphosphonate are comparable.
Key words: prostate cancer, bone metastases, bone loss, treatment.
|
| format | Article |
| id | doaj-art-4efaff1bfd10464d9aba6b9a88e57e80 |
| institution | Kabale University |
| issn | 0125-9326 2338-2732 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | Acta Medica Indonesiana |
| spelling | doaj-art-4efaff1bfd10464d9aba6b9a88e57e802025-08-20T03:40:57ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322013-01-01451Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer PatientsFerry Safriadi0Department of Urology, Faculty of Medicine, Padjajaran University - Hasan Sadikin Hospital Bandung, Indonesia Prostate cancer is a malignancy in urology with the highest incidence metastasize to the bone up to 70%. The incidence of skeletal related event (SRE) by 46.1% such as severe pain, pathologic fractures, spinal compression syndrome and hypercalcemia, with a consequence of higher inpatient care and worsen the patient’s prognosis. Androgen deprivation therapy (ADT) as a metastatic prostate cancer treatment itself causes an osteopenia or osteoporosis. Bisphosphonate inhibits normal and pathologic osteoclast-mediated bone resorption by several mechanisms. Denosumab is the latest treatment option in bone metastases. Multi-study shows the efficacy of denosumab is better than zoledronic acid for SRE prevention. Adverse events between denosumab and bisphosphonate are comparable. Key words: prostate cancer, bone metastases, bone loss, treatment. http://actamedindones.org/index.php/ijim/article/view/126 |
| spellingShingle | Ferry Safriadi Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer Patients Acta Medica Indonesiana |
| title | Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer Patients |
| title_full | Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer Patients |
| title_fullStr | Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer Patients |
| title_full_unstemmed | Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer Patients |
| title_short | Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer Patients |
| title_sort | bone metastases and bone loss medical treatment in prostate cancer patients |
| url | http://actamedindones.org/index.php/ijim/article/view/126 |
| work_keys_str_mv | AT ferrysafriadi bonemetastasesandbonelossmedicaltreatmentinprostatecancerpatients |